A study published in JAMA showed that ivonescimab, when combined with chemotherapy, improves progression-free survival in patients with non-small cell lung cancer who have the epidermal growth factor receptor (EGFR) variant. The study compared the efficacy of ivonescimab plus chemotherapy to chemotherapy alone in a double-blind, randomized phase 3 trial involving 322 participants. Results showed a significant improvement in progression-free survival with ivonescimab, especially in patients whose disease progressed while on EGFR-TKI treatment. The study, funded by Akeso Biopharma, concluded that ivonescimab plus chemotherapy is a tolerable and manageable treatment option for these patients.
Source link
Study shows ivonescimab improves progression-free survival in EGFR+ lung cancer
